Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

20.70
-0.2600-1.24%
Post-market: 20.700.00000.00%16:39 EST
Volume:1.63M
Turnover:33.53M
Market Cap:2.65B
PE:120.06
High:21.00
Open:20.33
Low:20.12
Close:20.96
52wk High:30.48
52wk Low:16.10
Shares:127.83M
Float Shares:78.12M
Volume Ratio:0.64
T/O Rate:2.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1724
EPS(LYR):0.1724
ROE:7.48%
ROA:3.53%
PB:7.15
PE(LYR):120.06

Loading ...

Apellis Names Former Pfizer CSO Mikael Dolsten to Board

Reuters
·
Yesterday

Apellis Announces Mikael Dolsten, M.d., Ph.d., to Join Board of Directors

THOMSON REUTERS
·
Yesterday

A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook

Simply Wall St.
·
Feb 28

Stock Track | Apellis Pharmaceuticals Plummets 5.17% Intraday Following Analyst Price Target Cuts and Neutral Ratings

Stock Track
·
Feb 25

Apellis price target lowered to $18 from $20 at Wedbush

TIPRANKS
·
Feb 25

Cantor Fitzgerald Remains a Buy on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Feb 25

Apellis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 25

Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Feb 25

Wedbush Adjusts Apellis Pharmaceuticals Price Target to $18 From $20, Maintains Neutral Rating

MT Newswires Live
·
Feb 25

Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Feb 25

Stock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses

Stock Track
·
Feb 24

Apellis Q4 product revenue driven by SYFOVRE sales

Reuters
·
Feb 24

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss

MT Newswires Live
·
Feb 24

Apellis Pharmaceuticals Q4 EPS $(0.47) Misses $(0.38) Estimate, Sales $199.913M Beat $199.222M Estimate

Benzinga
·
Feb 24

BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD 0.47

Reuters
·
Feb 24

Apellis Pharmaceuticals Q4 Operating Income USD -51.142 Million

THOMSON REUTERS
·
Feb 24

Apellis posts FY 2025 licensing and other revenue of USD 314.4 million, up 340%

Reuters
·
Feb 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 24

BRIEF-Apellis Announces Eight Oral Presentations At The 49Th Macula Society Annual Meeting

Reuters
·
Feb 19

Apellis to Present Eight Oral Talks at Macula Society Annual Meeting

Reuters
·
Feb 19